Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Beginning Cash Balance (2017 - 2018)

Niagen Bioscience (NAGE) has disclosed Beginning Cash Balance for 7 consecutive years, with $45.4 million as the latest value for Q1 2018.

  • On a quarterly basis, Beginning Cash Balance rose 2664.25% to $45.4 million in Q1 2018 year-over-year; TTM through Mar 2018 was $47.0 million, a 553.97% increase, with the full-year FY2013 number at $520000.0, up 23.76% from a year prior.
  • Beginning Cash Balance was $45.4 million for Q1 2018 at Niagen Bioscience, up from $429.0 in the prior quarter.
  • In the past five years, Beginning Cash Balance ranged from a high of $45.4 million in Q1 2018 to a low of $429.0 in Q3 2017.
  • A 5-year average of $9.8 million and a median of $3.1 million in 2014 define the central range for Beginning Cash Balance.
  • Peak YoY movement for Beginning Cash Balance: crashed 70.41% in 2017, then skyrocketed 2664.25% in 2018.
  • Niagen Bioscience's Beginning Cash Balance stood at $2.3 million in 2014, then soared by 75.33% to $4.0 million in 2015, then soared by 39.98% to $5.5 million in 2016, then plummeted by 99.99% to $429.0 in 2017, then soared by 10580086.48% to $45.4 million in 2018.
  • Per Business Quant, the three most recent readings for NAGE's Beginning Cash Balance are $45.4 million (Q1 2018), $429.0 (Q3 2017), and $1.6 million (Q2 2017).